RT Journal Article SR Electronic T1 2022-RA-704-ESGO Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OCRWE-Finland study JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP A257 OP A257 DO 10.1136/ijgc-2022-ESGO.549 VO 32 IS Suppl 2 A1 Rauhamaa, Heini A1 Herse, Fredrik A1 Isomeri, Outi A1 Idänpään-Heikkilä, Juhana A1 Käkelä, Sari A1 Hietanen, Sakari A1 Loukovaara, Mikko A1 Auranen, Annika YR 2022 UL http://ijgc.bmj.com/content/32/Suppl_2/A257.1.abstract AB Introduction/Background Ovarian cancer (OC) is a disease characterized by a dynamic treatment landscape in the real-life setting. The OCRWE-Finland study aims at describing the real-life burden of patients with OC, including treatment patterns, time to next treatment, disease characteristics and progression, survival, and healthcare resource utilization. This abstract reports on the observed treatment patterns.Methodology OCRWE-Finland is a multicentre, retrospective, noninterventional study collecting hospital medical records from university hospitals in Helsinki, Turku, and Tampere. Patients with ovarian, fallopian tube, or primary peritoneal cancer who were newly diagnosed as part of routine clinical care and received all OC treatments in these hospitals from 2014–2019 were included. Registry data were collected and combined by Findata (authorization holder), operating under the performance guidance of the Finnish Ministry of Social Affairs and Health.View this table:Abstract 2022-RA-704-ESGO Table 1 Baseline characteristic and first-line treatment patterns among patients with HGSOCResults In total, 1711 patients with OC (mean age=65.9 y, StDev=13.4 y) and 621 patients with high-grade serous OC (HGSOC) (mean age=68.0 y, StDev=10.1 y) were identified. Disease origin was ovaries in 75% of patients and peritoneum in 19%. Baseline characteristics and first-line treatment (TL1) patterns among patients with HGSOC can be found in table 1. During the observation period, 57% of patients received TL2, with 48% of these moving to TL3. The probability of undergoing TL2 was higher among stage III/IV patients and those with residual disease. In TL2, the most common treatment was platinum-based chemotherapy (32%); 26% received ‘other chemotherapy’, 33% of patients did not receive TL2 during this period but were still alive, and 9% died before initiating TL2.Conclusion This study documents real-life treatment patterns across lines of treatment among patients with OC and HGSOC during the first years of disease from the 3 biggest university hospitals in Finland. These results can provide useful baseline information about the rapidly evolving treatment landscape in OC in recent years.